UCLA Health Department of Medicine, Quality Office
Los Angeles, California, 90095, United States
NCT Number: NCT05586178
This study investigates different ways to elevate intentions to get the COVID-19 booster via text-based reminders, including providing information about the booster and leveraging the consistency principle. The proposed randomized controlled trial will examine the impact of these reminders on booster uptake.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Los Angeles, California, 90095, United States
The proposed randomized controlled trial will take place a few weeks after UCLA Health notified its patients about bivalent COVID-19 boosters. The trial will test whether text-based reminders can increase uptake of bivalent COVID-19 boosters and examine different ways to elevate intentions to get the booster. This trial will include a randomly selected ~40% of patients from all UCLA Health patients eligible to receive the COVID-19 bivalent booster at the time of the study, with 35% of the remaining eligible patients randomly allocated to another trial (Pre-registration title: "Boost intentions and Facilitate Action to Promote Covid-19 Booster Take-up") and 25% randomly allocated to a third trial (Pre-registration title: "Effects of Prompt to Bundle Covid-19 Booster and Flu Shot"). The three trials will be run simultaneously.
Patients randomly selected for this trial will be randomized at an equal share to 7 conditions: an Holdout condition that does not receive a text reminder and 6 additional conditions that receive a text message (simple reminder, uniqueness information reminder, eligibility information reminder, severity information reminder, consistency reminder, and consistency and uniqueness information reminder; see description in the Arm/Interventions section). Within each arm, patients are further randomized into one of the 33 time slots for when they will receive the text message (i.e., 3 time points per day including 9am, 12pm, 4pm for 11 days). Days 1-4 and 8-11 have slightly fewer patients than Days 5-7.
First, to test whether the text reminders increase vaccine uptake, the investigators will compare the holdout condition to the combination of the 6 reminder arms.
The investigators will also investigate additional questions:
Analysis:
The investigators will run ordinary least squares regressions (OLS) with robust standard errors to predict the aforementioned outcome variables, except that the investigators will use a Cox proportional hazards model with administrative censoring to predict time of obtaining the booster. The significance level will be 0.05. The regressions will include the following control variables:
The investigators will test whether the main effect of sending text reminders (i.e., the combination of the 6 reminder arms vs. holdout) is robust regardless of:
The investigators will investigate the following moderators for (1) the effect of sending a text reminder to facilitate action and (2) the effect of boosting intentions via information provision; since the investigators have competing predictions about the effectiveness of consistency framing, the investigators will exclude the arms containing consistency framing from this analysis:
Additional information: Three days into this trial, the investigators learned that the supply of boosters at UCLA Health is very limited and patients could not find appointments at UCLA Health. The investigators verified that local pharmacies continue to have appointments available. Thus, the investigators updated all text messages to (1) explain that UCLA Health has limited booster appointments available, (2) no longer provide a direct link to schedule appointments at UCLA Health, and (3) instead encourage patients to make an appointment at local pharmacies.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will receive a text message reminding them that they can now get the bivalent COVID-19 booster and facilitating action. The message will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find local pharmacies that carry the bivalent booster).
The message will leverage the psychological principle of consistency. It will highlight to patients that based on medical records, they have completed a COVID-19 vaccine primary series, have done a great job protecting their health, and can now get the bivalent booster.
The message will contain information about how the bivalent booster differs from previous doses patients have received and why it is valuable.
The message will clarify to patients that regardless of whether they are at high risk, received the original boosters, or previously got COVID-19, they are eligible for the bivalent booster based on their medical records, and the updated booster will be valuable for them.
The message will contain information about the often underestimated chances of people developing severe or long-lasting COVID-19 symptoms. The message will also mention that the bivalent booster can reduce such chances.
Time frame: 2 weeks after getting the text message
Whether people receive the bivalent booster at any location reporting to the California Immunization Registry (CAIR)
Time frame: 4 weeks after getting the text message
Whether people receive the bivalent booster at any location reporting to the California Immunization Registry (CAIR)
Time frame: 1 week after getting the text message
Whether people click on at least one link provided in the text message
University of California, Los Angeles
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05586204
COVID-19, Coronaviridae Infections
Los Angeles, California, United States
View Trial DetailsNCT05586165
COVID-19, Coronaviridae Infections
Los Angeles, California, United States
View Trial DetailsNCT05576623
COVID-19, Coronaviridae Infections
Gyeonggi-do, South Korea
View Trial DetailsNCT05593042
COVID-19, Coronaviridae Infections
Santiago, RM, Chile
View Trial Details